Restoring blood flow is central to acute ischaemic stroke treatment. But even after successful thrombolysis or thrombectomy, many patients are left with significant disability. Could additional treatments help improve outcomes? In the latest Voice of Stroke podcast episode, we explore new evidence on adjunctive therapies aimed at improving outcomes alongside reperfusion treatment, from early antiplatelet strategies to therapeutic hypothermia. This episode discusses: The TAPIS trial and whether early dual antiplatelet therapy after thrombolysis can improve functional outcomes New evidence from INSTANT and ATTRACTION examining the potential benefits and risks of intravenous tirofiban The ReCCLAIM II trial investigating rapid systemic cooling during mechanical thrombectomy as a potential neuroprotective strategy Featuring discussion of recent research published in The Lancet, Stroke and JAMA. Written by: Maria Magdalena Gabriel, Voice of Stroke Podcast Editor, and Linxin Li, Voice of Stroke Editor-in-Chief. Read the full transcript: https://eso-stroke.org/wp-content/uploads/ESO-podcast-November_transcript.pdf References 1. Wang A, Xia X, Tang Y, et al. Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial. Lancet. 2026;407:1919–1928. https://doi.org/10.1016/S0140-6736(26)00757-9 2. Zi X, He Y, Chen G, et al. Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. Stroke. 2026;57:2958–2970. https://doi.org/10.1161/STROKEAHA.126.057001 3. Chen HS, Cui Y, Li XQ, et al. Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. European Heart Journal. 2026;47:746–756. https://doi.org/10.1093/eurheartj/ehaf702 4. Liu X, Zhang F, Zhang C, et al. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. JAMA. 2026;335:1949–1958. https://doi.org/10.1001/jama.2026.5245 5. Huang H, Xu S, Qin T, et al. Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial. Lancet. 2026;408:263–274. https://doi.org/10.1016/S0140-6736(26)00983-9 6. Wang Y, Liao X, Feng S, et al. Tirofiban for Branch Atheromatous Disease–Related Stroke: The STRATEGY Randomized Clinical Trial. JAMA Neurology. 2026;83:956–964. https://doi.org/10.1001/jamaneurol.2026.2855 7. Li S, Hu H, Zhang D, et al. Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health – Western Pacific. 2026;75. https://doi.org/10.1016/j.lanwpc.2026.101995 8. Kass-Hout T, Horn C, Sun CHJ, et al. Adjuvant Systemic Hypothermia During Mechanical Thrombectomy (ReCCLAIM II): A Multicenter, Randomized, Controlled Trial. Stroke. 2026. https://doi.org/10.1161/STROKEAHA.126.056651 The Voice of Stroke podcast series is supported by an unrestricted educational grant from Bayer.